Phase II study of bevacizumab and irinotecan as second-line therapy in patients with metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and bevacizumab

ABSTRACT: Interventions: 1) Bevacizumab 10mg/kg is administered by 10-30min. intravenous infusion, followed by irinotecan 150mg/m2 by 90 min infusion (2)Patients should be received this chemotherapy biweekly until disease progression Primary outcome(s): Progression Free Survival Study Design: Single arm Non-randomized

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2620667 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR